Learn
Research peptide guides, in plain English.
What the molecules actually do, how the testing works, and what to look for before you trust a label. No marketing voice, no brand-name comparisons, just the science the way researchers talk about it.
Free Tool
Reconstitution Calculator
Enter vial mg + water mL + dose, get the exact insulin-syringe units to draw. Plus the worked math.
Reference
Peptide Glossary
A-Z definitions for every term you encounter in a research peptide COA, product page, or article.
Latest from the literature
Updated dailyHow GLP-1 peptides are being studied in people with HIV
People living with HIV tend to develop heart and metabolic problems earlier than the general population. Researchers are now asking whether a class of peptides can help.
Source: Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications. (Current opinion in HIV and AIDS, Haidar Lara et al.)
What researchers found when they studied GLP-1 peptides and multiple sclerosis
A registered systematic review pulled together every available study on GLP-1 peptides and MS. Here is what the evidence actually shows, and where the gaps remain.
Source: GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence. (Multiple sclerosis and related disorders, Sajjad Mobeen et al.)
How a GLP-1 peptide may help repair the brain after injury
What happens to the brain's protective barrier after a traumatic injury, and could a GLP-1 peptide help rebuild it? A recent mouse study explored the molecular chain reaction involved.
Source: Semaglutide promotes angiogenesis and blood-brain barrier repair after traumatic brain injury via PDGF-BB/PDGFRβ/Ang1/Tie2/VEGF signaling pathway. (Scientific reports, Shi Yuezhe et al.)
How weight loss research connects to gout and uric acid
Gout is often treated as a uric acid problem alone, but a new review argues that body weight may be just as central to the story.
Source: Hyperuricemia, gout and obesity: should weight management be more of a focus in gout management? (Nutrition, metabolism, and cardiovascular diseases : NMCD, Scilletta Sabrina et al.)
How GLP-1 peptides fit into peripheral artery disease research
Peripheral artery disease damages the vessels feeding the legs and arms. A major cardiology review now places GLP-1 receptor agonists near the center of emerging treatment research.
Source: Peripheral artery disease: advances in medical therapy. (European heart journal, Garagoli Fernando et al.)
How a small peptide tweak shifts receptor signaling in a big way
What happens when researchers modify just the tip of a peptide? A new cryo-EM study shows one structural shift can redirect how a major metabolic receptor fires its signals.
Source: N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement. (Cell reports, Zhao Li-Hua et al.)
How exercise may protect muscle during GLP-1 peptide treatment
GLP-1 peptides drive impressive fat loss, but lean mass often drops too. Researchers tested whether adding exercise could change that equation.
Source: Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk. (Diabetes & metabolism journal, Inia José A et al.)
Amylin analogs are emerging as a new class of obesity research tools
What is amylin, why do researchers care about it for obesity, and what do early-phase trials show about the newest long-acting analogs?
Source: Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. (Diabetes, obesity & metabolism, Alhazmi Abdulhameed et al.)
How researchers identify cyclic peptide drugs and their impurities
Cyclic peptides are notoriously hard to analyze. A new study shows how a refined mass spectrometry technique can map their structure and flag impurities that older methods miss.
Source: Strategies for the Identification of Cyclic Peptide Drugs and Their Impurities. (Journal of the American Society for Mass Spectrometry, Long Zhen et al.)
A slow-release gel system that kept a GLP-1 peptide working longer
What happens when you wrap a GLP-1 peptide in a gel that stays liquid in a syringe but turns solid inside the body? A new study tested exactly that.
Source: Thermosensitive Hydrogels for Sustained Semaglutide Release: Overcoming Weight Loss Plateau in Diet-Induced Obese Rats. (Pharmaceutical development and technology, Wang Jing et al.)
What a large meta-analysis found about incretin therapies and inflammation
Researchers pooled data from thousands of trial participants to ask: do incretin-based peptide therapies move the needle on inflammation, and if so, which markers change the most?
Source: Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis. (Diabetes, obesity & metabolism, Kanbay Mehmet et al.)
A phase 2 trial on liver fibrosis and a metabolic liver disease
Could combining two peptides reverse liver scarring in metabolic liver disease? A phase 2 trial across 22 countries tried to find out, with mixed results worth understanding.
Source: Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial. (The lancet. Gastroenterology & hepatology, Loomba Rohit et al.)
How next-generation peptides target obesity beyond weight loss
Researchers now measure more than pounds lost. A 2026 review tracks how newer peptide agents affect the heart, liver, kidneys, and more.
Source: Medical Treatments for Obesity: What Does the Future Have in Store? (The Journal of clinical endocrinology and metabolism, Bassatne Aya et al.)
A new acoustic tool maps brain activity during eating
How do brain circuits know a meal is happening? A new low-cost acoustic device lets scientists watch lateral hypothalamus neurons fire in real time during eating.
Source: The Crunchometer, a low-cost, open-source acoustic analysis of feeding microstructure. (eLife, Gil Lievana Elvi et al.)
How macrocyclic peptides are discovered using phage display
What makes a peptide drug candidate? A 2026 review explains the chemistry behind macrocyclic peptides and why their ring-shaped structures matter in early drug discovery.
Source: Hybrid Macrocyclic Peptides - Synthetic Strategies to Diversify and Cyclize Peptide Libraries in Phage Display Selections. (Chemistry (Weinheim an der Bergstrasse, Germany), Oppewal Titia Rixt et al.)
GLP-1 peptides and stopping insulin: what a large study found
Could adding a GLP-1 peptide help people with type 2 diabetes stop using basal insulin? A large U.S. veterans study ran the numbers, and the answer was more complicated than expected.
Source: Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation. (Annals of internal medicine, Lipska Kasia J et al.)
How GLP-1 receptor signaling interacts with heart muscle force
Researchers testing human atrial tissue discovered that stimulating GLP-1 receptors changed how the heart responded to a second signaling compound, raising new questions about cardiac signaling pathwa
Source: On indirect negative inotropic effects of muscarine in the isolated human atrium. (Naunyn-Schmiedeberg's archives of pharmacology, Neumann Joachim et al.)
Combining two neuroprotective compounds to limit stroke damage in mice
What happens in the brain after a stroke, and could two compounds working on different pathways do more together than separately? A mouse study dug into the molecular detail.
Source: Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice. (Neurochemical research, Yang Qinghuan et al.)
How researchers studied thymosin beta-4 alongside a common antibiotic on eye cells
When scientists tested a widely used eye antibiotic on corneal cells in the lab, they found concentration-dependent toxicity. Thymosin beta-4 helped with wound healing but could not fully reverse the
Source: Understanding the effects of ciprofloxacin on corneal epithelial cells: a study using electric cell-substrate impedance sensing (ECIS) technology. (Experimental eye research, Banga Loveleen et al.)
How a monomeric insulin analog could speed up blood sugar control
Most insulin slows down because molecules clump together before reaching the bloodstream. A new materials strategy may change that.
Source: Monomeric Insulin Analog and Stabilizing Excipient Enabled Ultrafast Insulin Formulation. (Advanced materials (Deerfield Beach, Fla.), Zhang Yanxian et al.)
How cheap could generic semaglutide actually get?
Researchers ran the numbers on production costs and patent timelines to figure out how affordable semaglutide could realistically become once generic versions enter the market.
Source: How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access. (Obesity (Silver Spring, Md.), Levi Jacob et al.)
GLP-1 peptides may directly affect mitochondrial energy output
Could a class of metabolic peptides be doing something useful deep inside cells, at the level of the mitochondria? A new meta-analysis digs into the early lab evidence.
Source: Direct effects of glucagon-like Peptide-1 receptor agonists on mitochondrial function in human-derived in vitro models: A systematic review and meta-analysis. (Metabolism open, Greenblatt Zoe Lee et al.)
Researchers review drug options for sleep apnea in older adults
Why is treating sleep apnea with medication so complicated in older adults, and what does current research say about the options being studied?
Source: Pharmacologic Treatment for Obstructive Sleep Apnea in Older Adults. (Drugs & aging, Jaganathan Nikhil et al.)
How researchers are redesigning a peptide antibiotic to fight resistant bacteria
Antibiotic resistance is one of the most pressing problems in medicine. A recent study details a systematic method for redesigning a peptide antibiotic to make it more potent against bacteria that alr
Source: Discovery of potent biphenyl-macolacin derivatives through a lysine-T/CDHA iterative scanning (LTIS) strategy followed by chemical ligation-based modifications. (Molecular diversity, Jing Xiaoshu et al.)
How researchers are approaching fatty liver disease with new drug classes
What does the current research say about treating the most common chronic liver disease worldwide, and which drug classes are scientists watching most closely?
Source: Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review. (Journal of obesity & metabolic syndrome, Chan Wah-Kheong et al.)
Small-molecule GLP-1R agonists and the prodrug approach researchers are exploring
Could redesigning a small molecule's chemical wrapper give it a slower, steadier release? Researchers say early lab data suggests yes, but in vivo proof is still needed.
Source: Lead-guided prodrug development of small molecules as GLP-1R agonists. (Bioorganic chemistry, Lentschat Hannah et al.)
A large cohort study links a dual receptor peptide to lower aortic stenosis rates
Could a dual-acting metabolic peptide do something no drug has done before: lower the odds of a stiff, narrowed heart valve? A large real-world study tried to find out.
Source: Tirzepatide and risk of newly diagnosed aortic stenosis in patients with obesity: a multi-institutional real-world cohort study. (BMC cardiovascular disorders, Wu Jheng-Yan et al.)
How GLP-1 receptor agonists affected weight and kidney markers in trials
Can a class of peptides lower a kidney stress marker even in people without diabetes? A large meta-analysis pulled data from 26,000 trial participants to find out.
Source: Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis. (The Journal of international medical research, Huang Rong et al.)
How GLP-1 may steer stem cells toward bone instead of fat
Could a metabolic peptide influence whether your bone marrow makes bone cells or fat cells? New research traces a molecular pathway that may explain the connection.
Source: GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis. (Stem cell reports, Yang Zhe et al.)
How AI now predicts the shapes of research peptides
AI can now sketch the 3-D shape of almost any peptide in seconds. A recent review breaks down what that means for research, and where the limits still are.
Source: AlphaFold-based peptide structure prediction: Opportunities, limitations, and future directions. (Biotechnology advances, Zhang Buke et al.)
How two incretin receptors talk to each other inside cells
What happens when two hormone receptors team up inside a pancreatic cell? New molecular research shows the pairing itself changes which signals get sent.
Source: GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways. (Cell chemical biology, Lindquist Peter et al.)
How nanoarchitectures could reshape peptide delivery for diabetes research
Peptides like insulin degrade fast and absorb poorly. Could tiny, bioinspired structures finally fix that? A 2026 review maps the latest laboratory answers.
Source: Peptide delivery in the management of diabetes: exploring bioinspired nanoarchitectures using stimuli-responsive materials and supramolecular depots. (International journal of pharmaceutics, Abdullahi Aliyu Dantani et al.)
How obesity drugs compare in the largest review to date
Which obesity drug works best, and at what cost? A massive new review pooled a quarter-million data points to find out.
Source: Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. (BMJ (Clinical research ed.), Nong Kailei et al.)
How a copper peptide hydrogel tackles diabetic wound healing
Diabetic wounds are notoriously hard to heal. A new hydrogel study shows how GHK-Cu could act as a chemical relay to address three problems at once.
Source: Copper peptide activated cascade catalysis for glucose regulation and hypoxia reversing in infected diabetic wound healing. (Materials today. Bio, Huang Zeng-Jin et al.)
Large cohort study flags safety signals for GLP-1 receptor agonists
What safety signals did researchers find when they tracked tens of thousands of real-world patients starting GLP-1 receptor agonists for weight loss?
Source: GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study. (Diabetes, obesity & metabolism, Park Jisu et al.)
A new chemistry trick for attaching groups to peptides
How do chemists attach new chemical groups to a peptide without wrecking the rest of the molecule? A published study shows one clever answer.
Source: Harnessing the Reactivity of Sulfinate Salts With Cystine: An Umpolung Approach to Residue-Specific Peptide Modification. (Angewandte Chemie (International ed. in English), Hammond Joshua M et al.)
A GLP-1 peptide is being studied for alcohol use disorder
Can a peptide best known for metabolic research also quiet the urge to drink? A phase-2 trial is trying to find out, and the early design offers a close look at what researchers expect to measure.
Source: Semaglutide Therapy for Alcohol Reduction (STAR) (NCT NCT06015893, status: RECRUITING)
How researchers measured tirzepatide's effects in type 1 diabetes with obesity
Can a dual gut-hormone peptide move the needle on blood sugar, body weight, and cardiovascular risk markers in people living with both type 1 diabetes and obesity? A recent real-world study tried to f
Source: Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers. (Diabetes, obesity & metabolism, Berry Simon A et al.)
How switching a receptor from on to off may amplify weight loss
What if a single peptide could act like an agonist first and then flip into an antagonist? Researchers built exactly that, and the results in obese mice were striking.
Source: A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice. (Diabetes, obesity & metabolism, Zhang Yunxiao et al.)
What researchers are learning about GLP-1 peptides and childhood obesity
A new review asks whether the same peptide class reshaping adult metabolic research can be responsibly studied in teenagers, and what the data say so far.
Source: GLP-1 receptor agonists in pediatric obesity. (Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Abodi Martina et al.)
A GLP-1 peptide and eosinophil counts: what researchers found
Eosinophils are white blood cells tied to allergic inflammation. A new real-world study asked whether a GLP-1 receptor agonist peptide changes how many circulate in the blood.
Source: Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study. (BMC pulmonary medicine, Wu Yiting et al.)
A pilot trial tests a metabolic peptide before knee surgery
Researchers are running a small controlled trial to find out whether giving a GLP-1 peptide before and after knee replacement is even feasible, and what it might do to pain and weight.
Source: Protocol for Novel Perioperative Optimization of Obese Osteoarthritic Patients pending Total Knee Replacement with glucagon-like peptide-1 receptor agonist (NPO-OOPS-TKR) : a pilot randomized controlled trial. (Bone & joint open, Lau Lawrence C M et al.)
How a GLP-1 peptide affects kidney filtering measurements
Can a peptide skew the lab numbers doctors use to track kidney health? A small clinical analysis looked closely at that question.
Source: Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate. (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Yahya Rafal et al.)
How long before incretin peptides show heart failure benefits
Researchers pooled data from more than 4,000 participants to pinpoint exactly when incretin peptides start making a measurable difference in a specific type of heart failure tied to excess weight.
Source: Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis. (Journal of cardiac failure, Spiazzi Bernardo F et al.)
How GLP-1 peptides compare in adolescents with obesity
Which GLP-1 receptor agonist moved the needle most on weight, blood sugar, and blood pressure in young people? A large meta-analysis tried to find out.
Source: GLP-1 Receptor Agonist Therapy in Children and Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles. (Pharmacological research, Li Yao et al.)
How a protein called PCSK5 may help hearts heal after a heart attack
Researchers found that a naturally occurring enzyme in blood vessel cells can trigger new vessel growth after a heart attack. Here is what that means.
Source: PCSK5 promotes angiogenesis and cardiac repair after myocardial infarction. (Nature communications, Guo Jieyu et al.)
GLP-1 receptor research enters the polycystic kidney disease conversation
Could a class of peptides known for metabolic effects also slow cyst growth in a common inherited kidney disease? A recent review maps out the scientific rationale and what still needs to be proven.
Source: GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing. (Translational research : the journal of laboratory and clinical medicine, Corrêa Lucas Maciel de Almeida et al.)
GLP-1 peptides and atrial fibrillation risk in kidney disease
Could a class of metabolic peptides also protect the heart's rhythm? A recent analysis of nearly 76,000 patients with chronic kidney disease offers some intriguing numbers.
Source: GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease. (Cardiovascular drugs and therapy, Dhamelia Parth et al.)
Why female mice kept their muscle during GLP-1 weight loss research
When researchers measured muscle mass and strength after GLP-1 peptide treatment, female mice held onto their muscle completely. Males did not get the same protection.
Source: Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice. (Diabetes, Rout Subhasmita et al.)
How researchers tested adding a GLP-1 peptide to weekly insulin
Can a GLP-1 receptor agonist peptide meaningfully improve blood sugar control when added to a weekly insulin already in use? A phase 3b trial measured exactly that.
Source: Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8). (Diabetes, obesity & metabolism, Strojek Krzysztof et al.)
Tiny needles in a patch may change how peptides are delivered
What if a dissolvable patch of microscopic needles could deliver a peptide through your skin as reliably as a shot? Researchers are working on exactly that.
Source: Enhanced Stability and Transdermal Delivery of Semaglutide Using an L-Arginine Based Dissolving Microneedle System. (AAPS PharmSciTech, Panchal Priyanka et al.)
How supercritical CO2 could make heart-focused peptides more effective
Peptides show real promise in cardiovascular research, but getting them into the body intact is surprisingly hard. A new review looks at an unexpected solution: pressurized CO2.
Source: Innovative Peptide Formulations for Cardiovascular Diseases Using Supercritical CO: A Comprehensive Review and Potential Applications. (European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, de Melo Silvio A B Vieira et al.)
How peripheral kappa opioid receptors shape pain and inflammation
Most opioid research focuses on the brain, but a growing body of work shows that kappa opioid receptors in peripheral tissues may offer a cleaner path to pain and inflammation control.
Source: Peripheral κ opioid receptor in pain and inflammation: From molecular signalling and gene expression to drug discovery. (British journal of pharmacology, Khan Rumsha et al.)
How a layered emulsion could help peptides survive the gut
Getting a peptide past the stomach and into the bloodstream by mouth is notoriously hard. A new formulation study shows one creative way digestion itself might solve the problem.
Source: Double emulsions enable in situ generation of permeation enhancers for oral delivery of macromolecules. (Journal of colloid and interface science, Pohlit Hannah et al.)
Researchers are testing a long-acting semaglutide implant in humans
What happens when a GLP-1 peptide is delivered by a removable implant instead of a weekly injection? A new trial is about to find out.
Source: Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant (NCT NCT07430059, status: NOT_YET_RECRUITING)
How newer glucose-lowering peptides may affect a tricky lung condition
Researchers pooled data from 128 randomized trials to ask whether newer glucose-lowering drugs shift the odds of developing a poorly understood overlap between asthma and COPD.
Source: Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials. (EClinicalMedicine, Zeng Bing-Yan et al.)
Dissolving mouth films may one day deliver GLP-1 peptides without injections
Could a dissolvable film placed inside the cheek replace an injection for peptide delivery? A 2026 materials-science study tested exactly that idea in the lab.
Source: Nanocomplexes Integrated into a Polymeric Bilayer Film Enhance Buccal Permeation of a GLP-1 Peptide Analogue. (ACS applied materials & interfaces, Karki Sandeep et al.)
A 24-week peptide trial in schizophrenia patients measured weight and gut changes
People with schizophrenia often gain significant weight from antipsychotic drugs. Researchers wanted to know whether a GLP-1 peptide could help, and what it does to the gut microbiome along the way.
Source: Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial. (Schizophrenia research, Lappin Julia M et al.)
One molecule, three targets: a new metabolic research direction
What happens when researchers combine three separate metabolic signals into one engineered molecule? A published abstract offers early preclinical answers.
Source: A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model. (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, Liu Yuxuan et al.)
What a meta-analysis found about retatrutide and cardiovascular markers
Researchers pooled randomized controlled trial data to ask one question: does retatrutide move cardiovascular markers, and by how much?
Source: Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. (High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, Simental-Mendía Luis E et al.)
How weight loss research is changing sleep apnea science
Can reducing body weight actually quiet the pauses in breathing that define sleep apnea? A recent review of randomized trials says the data are promising.
Source: [The role of obesity and weight reduction in obstructive sleep apnea]. (Orvosi hetilap, Horváth Gellért et al.)
What a systematic review found about GLP-1 research in younger patients
Researchers pooled data from 13 studies to ask whether GLP-1 receptor agonists move the needle on weight and blood sugar in younger populations, and what side effects appeared.
Source: GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety. (Diabetes research and clinical practice, Soliman Ashraf T et al.)
How GLP-1 peptides may affect the surface of the eye
Research is asking a new question: do GLP-1 receptor agonists change the surface of the eye, and if so, is the change helpful, harmful, or both?
Source: GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications. (Ophthalmology and therapy, Bair Henry et al.)
GLP-1 receptor agonists and cardiopulmonary risk in sleep apnea patients
What happens to heart and lung health when people with both sleep apnea and type 2 diabetes use GLP-1 receptor agonists instead of other diabetes medications?
Source: GLP-1 receptor agonists and Risk of Cardiovascular and Pulmonary Complications in patients with OSA and Type 2 Diabetes Mellitus. (Sleep & breathing = Schlaf & Atmung, Borissov Borissov Martin et al.)
GLP-1 receptor agonists and alcohol use: what researchers found
Could a class of peptides already studied for metabolic conditions also influence how much people drink? A new systematic review pooled data from nearly 50,000 participants to find out.
Source: Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence. (Journal of clinical medicine, Altami Ibrahim K et al.)
How a GLP-1 peptide changes eating without altering taste
Does a popular weight-loss peptide dull your sense of taste? New research in mice says probably not, and the real story is more interesting.
Source: Chronic semaglutide alters ingestive behavior without impairing taste function in mice. (Molecular metabolism, Acosta Alisha A et al.)
How changing a peptide's shape helps it reach injured kidneys
A new study shows that the physical topology of a polymer coating, not just its size or chemistry, controls where a therapeutic peptide ends up in the body.
Source: Topology-Controlled PEGylation Enhances Renal Accumulation of Therapeutic Peptide for Treating Ischemia-Reperfusion Injury. (Nano letters, Wen Yixing et al.)
How researchers engineered a cheaper way to make a GLP-1 peptide backbone
Making long-acting GLP-1 peptides is expensive and slow. A new lab strategy using fusion proteins and two-step cleavage may change that equation.
Source: High-yield recombinant production of the semaglutide main chain P29 intermediate using SNAC-tagged enterokinase-cleavable fusion peptides. (PloS one, Qi Qingyu et al.)
GLP-1 peptides and sleep apnea: what a large study found
Could a class of metabolic peptides influence serious health outcomes in people with sleep apnea? A large retrospective study set out to find numbers.
Source: GLP-1 Receptor Agonists in Obstructive Sleep Apnea: A Propensity Score-Matched Real-World Analysis. (Respiratory medicine, Rai Pranjal et al.)
How tiny mitochondrial signals behave during exercise in cerebral palsy
Could the body's smallest signaling proteins stay intact even when muscle mass and oxygen uptake are reduced? Researchers tested that question in people with cerebral palsy.
Source: Circulating mitochondrial-derived microproteins at rest and in response to an acute bout of endurance exercise in individuals with cerebral palsy. (Experimental physiology, Horwath Oscar et al.)
How GLP-1 peptides compare to bariatric surgery in real-world data
A new real-world study with more than 44,000 patients puts numbers on a question researchers have been circling for years: how much weight do GLP-1 peptides actually cause people to lose compared with
Source: Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. (Obesity (Silver Spring, Md.), Brown Avery et al.)
How researchers are trying to make a GLP-1 peptide work as a pill
Injectable GLP-1 peptides work well but require needles. Researchers built a tiny oil-droplet system to see whether the same peptide could survive the trip through the stomach and into the bloodstream
Source: Hydrophobic ion pairing formed semaglutide designed for oral self-microemulsifying delivery in diabetes treatment. (European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Zhang Yuhuan et al.)
A large trial is tracking heart events in type 2 diabetes
Can a once-daily oral peptide-based drug lower the risk of serious heart events in people with type 2 diabetes? A large NHS-linked trial is spending years finding out.
Source: A Study of Cardiovascular Events iN Diabetes Plus (NCT NCT05441267, status: ACTIVE_NOT_RECRUITING)
How a dual GLP-1 and GIP peptide may protect artery walls
A 2026 study tested whether activating two incretin receptors at once could slow the vascular damage behind one of the most dangerous artery conditions researchers study.
Source: Tirzepatide, a dual GIP/GLP-1 receptor agonist, attenuates endothelial dysfunction and angiotensin II-induced abdominal aortic aneurysm in ApoEmice. (Pharmacological research, Gómez-Martín Álvaro et al.)
What a large meta-analysis found about GLP-1 peptides and kidney disease
Can a class of gut-hormone peptides meaningfully reduce heart attack risk and kidney decline at the same time? A sweeping meta-analysis tried to find out.
Source: Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. (Diabetes, obesity & metabolism, Kaur Rashpinder et al.)
What researchers found when studying NMN, sleep, and brain SIRT1
Does NMN directly improve sleep quality? A recent animal study tested both short-term and long-term NMN dosing and came back with a surprising answer.
Source: Sleep-wake and circadian behavior in brain-specific sirtuin 1 knockout mice and effects of nicotinamide mononucleotide supplementation. (Scientific reports, Sakai Noriaki et al.)
How prion protein fragments may shape brain disease research
The protein best known for causing prion disease turns out to play a surprisingly broad role in how neurons survive, signal, and respond to toxic protein clumps.
Source: Cellular prion protein and its derived peptides: multifaceted roles in neurodegenerative diseases and potential as biomarkers. (Cell & bioscience, Mari Emanuela et al.)
How researchers are studying neuroprotection for glaucoma
Glaucoma research is moving beyond eye-pressure control. A published review explains which molecules researchers now believe could protect the nerve cells that glaucoma destroys.
Source: Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies. (Drug design, development and therapy, Rho Seungsoo et al.)
How researchers ranked obesity treatments for adolescents in a major review
Researchers pooled 42 clinical trials and 3,835 adolescents to ask a simple question: which obesity treatments work best, and does pairing a medication with lifestyle coaching change the answer?
Source: Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis. (JAMA pediatrics, Wan Ke-Wen et al.)
How researchers detect early peptide degradation without destroying the sample
What does peptide degradation actually look like at the molecular level, and can scientists catch it early enough to matter for quality control?
Source: ATR-FTIR spectroscopy coupled with multivariate analysis for monitoring degradation and secondary structure transitions in therapeutic peptide formulations. (Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, Godzo Hrisanta et al.)
How researchers detect peptides in dried blood samples
Scientists published a faster way to screen for dozens of peptides in blood. The method works on dried spots, which stay stable for months without refrigeration.
Source: Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. (The Analyst, Mazzarino Monica et al.)
Can your genes predict how well weight-loss peptides work?
Researchers are enrolling adults to find out whether a handful of gene variants can forecast who responds best to GLP-1 and dual GIP/GLP-1 peptide therapy for obesity.
Source: Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists. (NCT NCT07653412, status: RECRUITING)
How researchers are studying tirzepatide's effects on brain dopamine in alcohol use disorder
Could a metabolic peptide reshape how the brain responds to alcohol? A new trial is scanning dopamine receptors in real time to find out.
Source: Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) (NCT NCT07559500, status: RECRUITING)
MOTS-c activates metabolism but complicates cell repair function
What happens when a peptide that boosts cellular metabolism is applied to stem cells already stressed by obesity? A recent paper found the results were more complicated than expected.
Source: Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells. (Inflammation and regeneration, Xing Li et al.)
Single, dual, and triple incretin agonists reviewed across obesity research
What does current research say about single, dual, and triple incretin peptides, and why are scientists calling for more studies before drawing firm conclusions?
Source: GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists. (Diabetes, metabolic syndrome and obesity : targets and therapy, Abid Mahroz et al.)
What a large Cochrane review found about weight drugs and blood pressure
Researchers pooled data from eight randomized trials to ask a deceptively simple question: do approved weight-reducing drugs actually lower the risk of death or heart disease in people with high blood
Source: Long-term effects of weight-reducing drugs in people with hypertension. (The Cochrane database of systematic reviews, Spary-Kainz Ulrike et al.)
How copper peptide coating changed a bone scaffold's biology
What happens when you coat a tiny injectable scaffold with GHK-Cu? Researchers measured gene expression, mineralization, and vessel formation to find out.
Source: Hierarchical regulation and mechanism of "open-hollow-fibrous network" structures: Osteogenic-angiogenic coupling responses of poly(γ-benzyl-L-glutamate) microspheres. (Biomaterials advances, Su Jieyu et al.)
How MOTS-c may calm heart inflammation in diabetic rat models
Researchers studying diabetic rats found that a mitochondria-derived peptide called MOTS-c quieted a major inflammatory pathway linked to heart disease. Here is what they measured.
Source: Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model. (Experimental physiology, Mills Aimee R et al.)
What researchers found when studying GLP-1 peptides and lung safety
GLP-1 receptor agonist peptides are known for gut-related side effects, but what does the evidence say about their effects on the lungs and airways?
Source: Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals. (Cardiovascular diabetology. Endocrinology reports, Ahuja Aarushi et al.)
What happens to muscle when people lose weight on GLP-1 peptides
Losing fat sounds straightforward, but what happens to muscle along the way? A meta-analysis of seven randomized trials looked closely at that question for GLP-1 receptor agonists used at obesity dose
Source: Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs). (International journal of obesity (2005), Laverde Ligia Patricia et al.)
How a GLP-1 peptide may slow lung scarring in mice
Researchers found that a GLP-1 peptide cut lung scarring in mice by switching on a protein chain that slows cell aging. Here is what the study measured.
Source: Semaglutide exerts anti-pulmonary fibrosis effects by inhibiting cellular senescence through activation of the Sirt1/HSF1/HSPs pathway. (Biochemical pharmacology, Qian Zeng et al.)
How researchers are snapping peptides together like building blocks
What if you could snap different peptide pieces together like modular components instead of rebuilding the whole molecule from scratch every time? A recent abstract describes exactly that.
Source: Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics. (Chemistry (Weinheim an der Bergstrasse, Germany), Kostadinova Kristina A et al.)
How scientists are mapping the structure of stapled peptides
Stapled peptides are among the most structurally intricate molecules in research chemistry. A new analytical method finally gives scientists a clear way to read their internal architecture.
Source: Mass Spectrometry-Based Structural Characterization and Reaction Kinetics Profiling of Stapled Peptides through Enzymatic Linearization. (Analytical chemistry, Gong Zijian et al.)
How researchers are solving the biggest problems with therapeutic peptides
Peptides have enormous research potential, but short lifespans in the body have slowed progress. A new review explains the strategies scientists are using to change that.
Source: Therapeutic Peptides as Targeting Vectors and Smart Therapeutics: Emerging Trends and Future Perspectives. (Current protein & peptide science, Ng Ivana Valencia et al.)
GLP-1 receptor agonists studied alongside inflammatory bowel disease therapies
Do GLP-1 receptor agonists change outcomes for people managing inflammatory bowel disease with obesity or diabetes? A recent trial emulation dug into the numbers.
Source: Adjunctive GLP1 Receptor Agonists in Patients with Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation. (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Yeh Kuan-Hung et al.)
How three obesity treatments compared after one year in real-world data
Researchers pooled records from more than 1,600 hospitals to see how two peptide-based treatments stacked up against a surgical option after 12 months.
Source: 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study. (The lancet. Diabetes & endocrinology, Leslie Daniel B et al.)
A major physician group ranks weight-loss peptides by evidence
Which peptide-based treatments did a major U.S. physician organization put at the top of its 2026 obesity guideline, and how strong is the evidence behind each ranking?
Source: Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026). (Annals of internal medicine, Qaseem Amir et al.)
How different GLP-1 peptides compared on kidney outcomes in diabetes
Do all GLP-1 receptor agonists protect the kidneys equally? A recent analysis of hundreds of thousands of patient records suggests the answer may be no.
Source: Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. (American journal of kidney diseases : the official journal of the National Kidney Foundation, Neumiller Joshua J et al.)
How antidiabetic peptides affect fat and lean mass
Which antidiabetic agents trim the most fat, and do they also shrink lean muscle? A large systematic review crunched 41 trials to find out.
Source: Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis. (Diabetes, obesity & metabolism, Rakhsha Seyedeh Samira et al.)
GLP-1 peptides and aesthetic surgery: what the research shows
Researchers reviewed what happens when people using GLP-1 receptor agonists undergo aesthetic and body contouring surgery, and the findings suggest some important perioperative considerations.
Source: GLP-1 Receptor Agonists in Aesthetic Surgery: A Narrative Review on Perioperative Safety, Sarcopenic Morphologies, and Adapted Body Contouring Strategies. (Aesthetic plastic surgery, Venza Mario et al.)
What a large meta-analysis found about GLP-1 peptides and heart failure
Researchers pooled data from 18,184 patients to ask one question: do GLP-1 receptor agonist peptides meaningfully change outcomes for people living with heart failure?
Source: Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis. (Cureus, Muller Ferreira Vicky et al.)
How a large review compared weight-management peptides head to head
Which peptide-based treatments showed the greatest weight loss in the largest comparison to date, and what did researchers find about safety trade-offs?
Source: Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. (Annals of internal medicine, Damen Johanna A A et al.)
Large database study maps drugs linked to gastric motility problems
Which drug classes showed the strongest statistical signals for gastric motility problems in a study covering more than 58 million adverse event reports?
Source: Drug-induced gastric motility disorders: A disproportionality analysis from the FAERS and CVARD databases. (PloS one, Qian Zhiheng et al.)
A rare esophageal rupture linked to a GLP-1 receptor agonist
What happens when forceful vomiting, drug-induced gastroparesis, and a skipped dose-titration period collide? One case report offers a sobering look.
Source: Boerhaave's syndrome associated with glucagon-like peptide-1 receptor agonist use: a case report. (Journal of cardiothoracic surgery, Aubrey Jason M et al.)
How GLP-1 receptor agonists affected glucose during Ramadan fasting
Researchers used continuous glucose monitors to track what happens to blood sugar across the Ramadan fasting day, and whether adding a GLP-1 receptor agonist to insulin made a measurable difference.
Source: GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study. (Diabetes research and clinical practice, Ashraf Tanveer et al.)
How researchers mapped herb interactions with GLP-1 receptor agonist side effects
Researchers pulled a decade of FDA safety reports and ran them through a graph-based AI model to ask: do common medicinal herbs share molecular targets with GLP-1 drug side effects?
Source: Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity. (Scientific reports, Park Junkyu et al.)
Can a metabolic peptide lower atrial fibrillation after ablation?
Roughly one in three ablation patients sees their atrial fibrillation return. Researchers want to know if a metabolic peptide started weeks before the procedure can change that outcome.
Source: Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation (NCT NCT07382024, status: NOT_YET_RECRUITING)
How thymosin beta-4 may support corneal nerve repair after infection
Can a peptide help the eye's nerves grow back after a serious infection? A published study tested exactly that, and the results point toward a meaningful role for thymosin beta-4.
Source: Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function. (Investigative ophthalmology & visual science, Ebrahim Abdul Shukkur et al.)
How stopping a GLP-1 peptide before surgery affects complications
Researchers tracked 80 patients on a GLP-1 peptide before body-contouring surgery. The timing of when they stopped the peptide made a striking difference in 30-day complication rates.
Source: Impact of Preoperative Semaglutide Discontinuation Timing on Postoperative Outcomes in Aesthetic Abdominoplasty: A Retrospective Comparative Study. (Aesthetic plastic surgery, Bruno Agostino et al.)
What happens when incretin peptides are paired with lifestyle changes
Researchers pooled data from 35 independent trials to find out whether pairing incretin-based peptides with lifestyle programs produces greater weight changes than lifestyle alone.
Source: GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. (Nutrients, Bruna-Mejias Alejandro et al.)
A new chemistry platform puts radioactive labels directly onto peptides
Why does radiolabeling matter in peptide research, and what makes this new hydroformylation approach different from older tagging methods?
Source: Late-stage generation ofC/H-radiolabeled lysine residues via hydroformylation of peptides. (Nature communications, Schick Anika et al.)
How chemists modify peptides to improve how they work
Why does the same peptide backbone sometimes behave very differently depending on small chemical additions? A recent minireview breaks down the toolkit researchers use to answer that question.
Source: Late-Stage Functionalization of Peptides on the Solid Phase. (Angewandte Chemie (International ed. in English), Werner Marius et al.)
GLP-1 peptides and heart failure risk in rheumatoid arthritis
What happens to heart and respiratory failure rates when people with rheumatoid arthritis and obesity use GLP-1 peptides? A new cohort study offers early, hypothesis-generating numbers.
Source: GLP-1-based therapy and ICD-10-documented heart failure or respiratory failure events in non-diabetic adults with rheumatoid arthritis and obesity: a TriNetX federated cohort study. (Clinical rheumatology, Loizidis Giorgos et al.)
A greener way to build therapeutic peptides in the lab
Why does it matter how peptides are built? A new study suggests a chemistry shortcut could make research-grade peptides cheaper, purer, and far easier on the environment.
Source: Towards Sustainable Synthesis of Peptide Therapeutics via Tag-Assisted Peptide Synthesis and Aryl Selenoester Aminolysis Ligation. (Journal of the American Chemical Society, Egelund Peter H G et al.)
How a GLP-1 peptide quieted brain inflammation in mice
Researchers traced the step-by-step cellular story of how a GLP-1 receptor agonist dampened brain inflammation in mice, and the pathways they found overlap with human neurodegenerative disease.
Source: Semaglutide attenuates neuroinflammation in male mice. (Nature communications, Belmont-Rausch Dylan M et al.)
What researchers found when testing metabolic peptides for liver disease
A systematic review of 12 clinical studies asks whether metabolic therapies originally built for blood-sugar control can also quiet dangerous liver inflammation.
Source: SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review. (European journal of clinical pharmacology, Cruz Artur Macedo et al.)
Who faces higher hypoglycemia risk on weekly semaglutide injections
Counterintuitively, patients with lower body weight and already-controlled glucose levels showed the highest hypoglycemia risk in a new semaglutide study. Here is what the researchers found.
Source: Risk Factors for Hypoglycemia in Type 2 Diabetes Mellitus Patients Using Once-Weekly Semaglutide: A Matched Case-Control Study. (Therapeutics and clinical risk management, Amirthalingam Palanisamy et al.)
Incretin peptides and eye nerve signals in real-world data
What does a large adverse-event database reveal about incretin peptides and a rare condition affecting the eye's optic nerve? A new analysis tries to find out.
Source: Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data. (Diabetes, obesity & metabolism, Kakkar Ashish Kumar et al.)
How ketone esters may protect muscle during GLP-1 weight loss
GLP-1 drugs cut weight fast, but up to 45% of that loss may be muscle. New mouse data asks whether ketone esters can close that gap.
Source: Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters. (JCI insight, Abuetabh Yasser et al.)
How GLP-1 peptides may protect both liver and heart
A new review asks whether one class of peptides can address fatty liver and heart risk at the same time. Here is what the trial evidence actually shows.
Source: GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes. (Chronic diseases and translational medicine, Amorim Moreira Alves Gabriel et al.)
GLP-1 receptor agonists and age-related eye disease risk
Can a class of metabolic peptides change the odds of common age-related eye diseases? A retrospective study of more than 68,000 adults suggests the association is worth watching closely.
Source: Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists. (Diabetes, obesity & metabolism, Chen Kuo-En et al.)
Why GLP-1 peptides produce different weight loss results depending on diabetes status
New research covering 45 studies asks why the same peptide therapy leads to very different weight outcomes, and diabetes status turns out to be the biggest factor.
Source: Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations. (Surgical endoscopy, Jia Iwanger-I-Ter T et al.)
How cagrilintide signals the brainstem to regulate food intake
Researchers mapped half a million brainstem cells across three species to pinpoint exactly which neurons carry cagrilintide's signal. The answer centers on a small cluster most scientists had overlook
Source: A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. (Nature metabolism, Ludwig Mette Q et al.)
How a dual gut hormone peptide affected fatty liver in mice
Researchers used full liver transcriptomic and proteomic mapping to explain why a dual GIP/GLP-1 peptide appears to calm fat buildup and inflammation in a mouse model of metabolic liver disease.
Source: Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis. (BMC gastroenterology, Pan Yongning et al.)
How six tissues talking to each other shapes glucose regulation
What happens when six human metabolic tissues share the same fluid? A preprint study built that system and found the answer is far more complex than any single-tissue model suggested.
Source: Inter-organ communication shapes human metabolic tissue states and resolves anti-diabetic drug response modes in a six-tissue microphysiological system. (bioRxiv : the preprint server for biology, McGilvrey Marissa et al.)
How delivery route changes what GHK-Cu does in aging brains
Same peptide, two delivery routes, two totally different biological programs in the hippocampus. A 2026 preprint unpacks what that means for aging research.
Source: Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. (Research square, Mazzola Jordan et al.)
GLP-1 receptor agonists and chronic low back pain: what a pilot study found
Researchers wanted to know whether a class of peptides that lower blood sugar and body weight might also change pain scores in people with chronic low back pain. Here is what a 12-month pilot study me
Source: Impact of GLP-1 Receptor Agonists on Chronic Low Back Pain in Patients with Obesity: A Prospective Pilot Cohort Study. (medRxiv : the preprint server for health sciences, Benedict Braeden et al.)
How a dual-receptor peptide affected metabolism in psoriasis patients
Researchers tracked body weight, cholesterol, blood sugar, and liver enzymes in psoriasis patients who also had obesity. What did 24 weeks of low-dose peptide therapy show?
Source: Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study. (Dermatology and therapy, Gisondi Paolo et al.)
How researchers map the hidden bonds inside cyclic peptides
Cyclic peptides fold their shape around hidden sulfur bonds. A new lab workflow can now map those bonds with far greater accuracy than older methods allowed.
Source: A targeted partial reduction Cyanylation strategy coupled with HRMS for accurate disulfide bridge mapping in Disulfide rich cyclic peptides. (Journal of chromatography. A, Chaturvedi Sachin et al.)
What researchers measured when using lower semaglutide doses for obesity
Most trials test the highest approved doses. This study asked what happens at lower doses in a real clinical setting, and the measurements surprised some researchers.
Source: Real-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in patients with obesity: a prospective observational study. (Scientific reports, Miertová Zuzana et al.)
A large study looks at GLP-1 peptides and eye disease risk
Does a widely used GLP-1 peptide raise or lower the risk of a vision-threatening eye condition? A large observational study tried to find out.
Source: Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study. (Ophthalmology, Cai Cindy X et al.)
Why oral GLP-1 peptides are so hard to absorb
Oral peptide drugs face a brutal gauntlet in the gut. A 2026 modelling study explains exactly where the losses happen and what researchers are doing about it.
Source: Steady-state pharmacokinetics of oral semaglutide using semi-mechanistic pharmacokinetic modelling and population simulations. (Xenobiotica; the fate of foreign compounds in biological systems, Tiwari Ayushi et al.)
GLP-1 receptor agonists linked to lower knee replacement rates in large study
Could a class of metabolic peptides slow knee osteoarthritis enough to delay or prevent joint replacement surgery? A large real-world study crunched the numbers.
Source: Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis. (Regional anesthesia and pain medicine, Carter Victoria et al.)
How blocking one enzyme may protect muscle during weight loss
GLP-1 receptor agonists drive meaningful weight loss, but research suggests they may also shrink muscle. A new mouse study explores whether blocking a single enzyme could change that outcome.
Source: 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss. (Proceedings of the National Academy of Sciences of the United States of America, Nalbandian Minas et al.)
How engineered vesicles delivered an anti-amyloid peptide to neurons
What happens when researchers attach a peptide designed to block amyloid clumping onto tiny natural-looking delivery vehicles and expose neurons to it?
Source: Engineered EV-mediated delivery of an anti-amyloid peptide provides neuroprotection in an in vitro Alzheimer's disease model. (International journal of pharmaceutics, Singh Varsha Birendra et al.)
How two metabolic receptors may quiet dopamine signals in the brain
Researchers found that activating gut-hormone receptors in a specific brain region reduced dopamine activity, raising new questions about how metabolic peptides interact with reward circuits.
Source: Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine. (ACS chemical neuroscience, Buchanan Anna Marie et al.)
GLP-1 peptides and eating disorders: what researchers are asking
GLP-1 receptor agonists are reshaping metabolic research, but a new spotlight article warns the field has not yet answered some important questions about eating behavior and psychological risk.
Source: Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities. (The International journal of eating disorders, Škudar Stjepan et al.)
How NMN may protect the liver from alcohol-related fat buildup
Researchers found that boosting NAD levels with NMN reversed a key liver protein deficiency and cut down fat accumulation in alcohol-fed mice. Here is what the data actually showed.
Source: Hepatic Hamp restoration contributes to nicotinamide mononucleotide (NMN)-alleviated hepatic steatosis in chronic alcohol-fed mice. (Communications biology, Cao Feiwei et al.)
GLP-1 peptides and survival after emergency stroke surgery
Could a peptide taken before a stroke change what happens afterward? A large retrospective analysis looked at exactly that question in patients who needed emergency clot-removal procedures.
Source: GLP-1 receptor agonists and post-endovascular thrombectomy outcomes in acute ischemic stroke: a multicenter propensity score matched analysis. (Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, Rai Pranjal et al.)
How GLP-1 peptides may affect fat graft survival
Millions of people using GLP-1 peptides for weight loss are also candidates for fat grafting. A new review asks whether these two things can coexist.
Source: Do GLP-1 Receptor Agonists Sabotage Fat Grafts? : A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer. (Aesthetic surgery journal, Chalhoub Xavier et al.)
What a large meta-analysis found about GLP-1 peptides and heart outcomes
Fifteen randomized trials, nearly 100,000 participants, and one clear signal: researchers found GLP-1-based therapies were tied to better cardiovascular outcomes as a class.
Source: The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis. (Diabetes, obesity & metabolism, Chuang Shih-Ming et al.)
A case report links GLP-1 receptor activity to prolactin changes
Researchers flagged a puzzling hormone shift in a patient using a GLP-1 peptide. Here is what the case report found and what questions it raises.
Source: Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto's Thyroiditis. (Case reports in medicine, Guimarães Gabriela N F et al.)
A phase 2 trial tests a GLP-1 peptide after brain bleeds
Can a weekly injectable peptide already known for metabolic research do anything useful after a brain bleed? A phase 2 trial across three Chinese medical centers is designed to find out.
Source: GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial (NCT NCT07613437, status: NOT_YET_RECRUITING)
GLP-1 peptides studied in liver transplant patients with weight gain
What happens when researchers track GLP-1 peptide use in liver transplant patients? A new multicenter study offers some of the clearest data yet.
Source: Safety, tolerability and efficacy of GLP-1 receptor agonists (GLP-1 RA) in the management of post-liver transplant weight gain: A multicenter, observational study. (Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, Khan Mohammad Qasim et al.)
How GLP-1 receptor agonists affect the body beyond weight
Researchers reviewed dozens of trials to ask whether obesity medications do anything useful beyond shrinking fat mass. The answer, the literature suggests, is yes, and the list is long.
Source: Beyond weight loss: multisystem benefits of obesity medications. (The lancet. Diabetes & endocrinology, Savas Mesut et al.)
GLP-1 peptides reduce fat but may also trim lean mass
Researchers compared 17 GLP-1 drug variations across 43 trials. Fat dropped, but lean mass took a hit at higher doses. Here is what the data showed.
Source: Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. (Diabetes, obesity & metabolism, Wachiraphansakul Nuttaya et al.)
How diabetes and two drug classes reshape kidney gene activity
A 2026 study sequenced the entire gene activity of a tiny kidney segment to understand how diabetes and two classes of metabolic drugs change cellular behavior at the molecular level.
Source: Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism. (American journal of physiology. Renal physiology, Kim Young Chul et al.)
How GLP-1 receptor research connects diabetes and stroke risk
Researchers reviewing major cardiovascular trials ask whether a class of incretin-based peptides does more than lower blood sugar, and what the current evidence actually supports.
Source: Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists. (Pharmaceutics, Paceana Maria-Alexandra et al.)
Silk nanoparticles could make oral peptide delivery more practical
Most peptide drugs have to be injected because the gut destroys them. A new nanoparticle platform made from silk may change that equation.
Source: Functional Performance of Silk Nanoparticles for Oral Drug Delivery. (ACS applied materials & interfaces, Jacobus Charlotte et al.)
How a GLP-1 peptide may protect bone cells in diabetic gum disease
Researchers found that a long-acting GLP-1 peptide blocked a damaging iron-driven cell death pathway in bone cells stressed by a diabetic environment. Here is what the study measured.
Source: Semaglutide Inhibits Osteoblast Ferroptosis Induced by Diabetic Periodontitis via Modulating the Wnt5a/Ror2/p38 MAPK Signaling Pathway. (Drug design, development and therapy, Zhang Zhen et al.)
GLP-1 receptor peptides and what researchers found in eye tissue
GLP-1 receptor peptides are studied mostly for blood sugar and weight. A new review asks what happens to the eyes, and the answer turns out to be complicated.
Source: Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists. (Vision (Basel, Switzerland), Lixi Filippo et al.)
How BPC-157 was studied in muscle tissue after blood flow injury
When blood flow is cut off and then restored, the returning oxygen can paradoxically destroy tissue. Researchers tested whether BPC-157 could interrupt that process.
Source: Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. (Scientific reports, Yıldırım Alperen Kutay et al.)
Why BPC-157 research still faces major development hurdles
BPC-157 has a rich preclinical record, yet no approved formulation exists. A 2026 review explains exactly what pharmaceutical science still needs to answer.
Source: BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. (Pharmaceutics, Mateescu Diana-Maria et al.)
How scientists read the fingerprints of complex peptides
Why is identifying a cyclic or chemically modified peptide so hard, and what did researchers build to fix that problem?
Source: Structure-aware fragment assignment for interpreting tandem mass spectrometry of modified and cyclic peptides. (The Analyst, Erckes V et al.)
How a GLP-1 peptide may protect the brain after diabetic hemorrhage
Researchers found that a GLP-1 receptor agonist blocked a damaging immune cascade inside brain blood vessels after hemorrhage, pointing to a molecular path that had not been described before.
Source: Semaglutide targets the Isg15-FUNDC1 axis: suppressing IFN-β overactivation and attenuating blood-brain barrier injury in diabetic intracerebral hemorrhage. (Journal of neuroinflammation, Wang Yan et al.)
New computational tools map how proteins misbehave at scale
Why do some proteins clump into harmful fibers while others form temporary liquid compartments? A new computational framework gives researchers a fast way to find out across the whole human proteome.
Source: amyloid-predict and LLPS-predict: Predicting phase separation propensities in the intrinsically disordered proteome. (Proceedings of the National Academy of Sciences of the United States of America, Lobo Samuel et al.)
GLP-1 research in schizophrenia spectrum disorders explained
People with schizophrenia spectrum disorders face unusually high rates of obesity. Researchers pooled trial data to see whether a GLP-1 peptide could shift that picture.
Source: The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials. (BJPsych open, Trott Mike et al.)
What a large meta-analysis found about cagrilintide and weight
Researchers pooled data from thousands of participants to see how a long-acting amylin analogue stacks up against placebo for weight and cardiometabolic outcomes.
Source: Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. (Journal of diabetes and metabolic disorders, Rao Hammad et al.)
A large study maps health outcomes tied to GLP-1 diabetes drugs
What happens across hundreds of health measures after someone with type 2 diabetes is prescribed a GLP-1 receptor agonist? A large real-world study tried to find out.
Source: Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us. (Nature communications, Salvatore Maxwell et al.)
A new trial asks whether a metabolic peptide can help people quit smoking
Researchers at four major universities want to know whether tirzepatide, a peptide that targets two metabolic hormones at once, might make it easier for people with overweight or obesity to stop smoki
Source: Multi-Site Trial of Tirzepatide for Smoking Cessation (NCT NCT07602699, status: RECRUITING)
Why combining two gut hormones may outperform one alone
Researchers are asking why pairing two gut-hormone pathways produces stronger metabolic results than targeting either one on its own. A major review unpacks the science.
Source: The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms. (Annual review of nutrition, Davies Iona et al.)
How weight loss therapies can affect bone and muscle health
Weight loss sounds straightforwardly good, but researchers are asking whether it also quietly weakens bone and muscle, and what the evidence actually shows.
Source: Breaking Point: Weight Loss Therapies and the Musculoskeletal Stakes (Endocrine News)
Combining a GLP-1 peptide with sleeve surgery: what researchers found
Can a short course of a GLP-1 peptide after bariatric surgery push outcomes further? A 2026 prospective study measured exactly that over twelve months.
Source: Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study. (Obesity surgery, Huang Yi Shan et al.)
What a clinical trial found when researchers infused GIP for six weeks
GIP is one half of a celebrated hormone pair. A rigorous trial just tested it head-on for glucose control, and the results were more complicated than expected.
Source: Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial. (The lancet. Diabetes & endocrinology, Helsted Mads M et al.)
When bariatric surgery falls short, a peptide trial offers new data
Bariatric surgery does not always produce the expected weight loss. A 68-week trial now gives researchers hard numbers on whether a GLP-1 receptor agonist peptide can close that gap.
Source: Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial. (Nature medicine, Stanley Chloe et al.)
GLP-1 peptides and heart failure: what the research shows
Researchers reviewed whether GLP-1 receptor agonist peptides, first studied in diabetes, might change outcomes for people living with heart failure.
Source: [Glucagon-like peptide-1 agonists and heart failure]. (Revue medicale suisse, Soborun Nisha et al.)
How weight loss affects the brain, according to researchers
Can losing a substantial amount of weight measurably change how the brain uses oxygen and processes information? A forthcoming trial is designed to find out.
Source: Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss (NCT NCT07592546, status: NOT_YET_RECRUITING)
How GLP-1 receptor agonists may affect fatty liver disease
Researchers reviewed dozens of studies to explain why a class of metabolic peptides seems to help with fatty liver disease, and the answer involves at least four overlapping biological networks.
Source: GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and translational implications: a review. (Journal of endocrinological investigation, Wang Xuejia et al.)
GLP-1 peptides and unusual skin sensations: what researchers found
Social media reports of burning skin during GLP-1 peptide use prompted a formal database review. Researchers found a real signal, and the findings are worth understanding.
Source: Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. (European journal of clinical pharmacology, Laroche Marie-Laure et al.)
A new trial is testing a GLP-1 peptide for cocaine use disorder
No FDA-approved drug exists for cocaine use disorder. Researchers are now testing whether a peptide that acts on the brain's reward system could change that picture.
Source: Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial. (BMJ open, Yammine Luba et al.)
What happens to the body when incretin therapy stops
Millions of people stop incretin-based medications within a year. A major review asks what that stopping actually does to the heart, blood sugar, and body weight.
Source: Causes and consequences of discontinuation of GLP1RAs or tirzepatide. (Nature reviews. Endocrinology, Ceriello Antonio et al.)
A GLP-1 peptide slowed biological aging clocks in a randomized trial
Could a peptide that targets metabolic receptors also slow how fast the body ages at a molecular level? A randomized trial measured exactly that.
Source: Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. (Nature communications, Corley Michael J et al.)
A dual GIP/GLP-1 peptide reduced protein in urine for Fabry patients
Could a metabolic peptide do kidney-protective work in a rare genetic disease? A recent abstract tested exactly that idea in 15 patients.
Source: DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic fabry disease. (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Riccio Eleonora et al.)
What a major review found about peptides and sports recovery
Peptides are being used in sports medicine faster than research can keep up. A 2026 review mapped exactly where the evidence stands and where it falls short.
Source: Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. (JBJS reviews, Villegas Meza Alan D et al.)
Library guides
Research Peptides 101: A Plain-English Primer
What peptides are, why purity matters, and how to read a Certificate of Analysis without a chemistry degree.
GLP-1 Receptor Research: Single, Dual, and Triple Agonists
From single-target GLP-1 agonists to triple agonists hitting GLP-1, GIP, and glucagon. Mechanism, generations, and what the next wave of research looks at.
BPC-157: Mechanism of Action and Research Overview
A fragment of a gastric protein became one of the most-studied peptides in connective-tissue research. Here is what the literature actually shows.
Growth Hormone Peptides: Secretagogues, Releasing Hormones, and IGF-1
Native growth hormone has a half-life of about 17 minutes. Here is how the peptides that prompt it, mimic it, and amplify it actually work.
Recovery and Repair Peptides: BPC-157, TB-500, GHK-Cu, and KPV
Four peptides, four different mechanisms, one shared research focus: getting damaged tissue to heal faster than it would on its own.
NAD+, MOTS-c, and Mitochondrial Research Peptides
Mitochondria have their own genome and encode their own peptides. Here is what the research on NAD+ and MOTS-c suggests about cellular energy metabolism.
Cognitive Peptides: Semax, Selank, Pinealon, and DSIP
Russian research labs spent four decades studying short peptides for cognitive and mood endpoints. Here is what the literature on Semax, Selank, Pinealon, and DSIP actually shows.
How to Read a Certificate of Analysis
A COA is the lab report that backs up the label. Here is what each section means and the three things that should make you stop and ask questions.
Bacteriostatic Water and Reconstitution: A Practical Primer
Sterile water and bacteriostatic water are not the same thing. Here is the difference, and the simple math that turns a 10mg vial into a known concentration.
Retatrutide Research Overview: The Triple Agonist
Retatrutide is the most-studied triple agonist on the metabolic receptor axis. Here is the mechanism, what the studies looked at, and the open questions.
Tesamorelin Research Overview: A GHRH Analog for Visceral Fat
Tesamorelin is one of the few growth-hormone-axis peptides with a clean FDA-approval history. Here is the mechanism and what the published data looked at.
PT-141 Research: A Centrally Acting Melanocortin Agonist
PT-141 acts on melanocortin receptors in the central nervous system, not on the vasculature. Here is what the receptor literature suggests about the mechanism.
Thymosin Alpha-1 Immune Research Overview
Thymosin alpha-1 has been studied in immune research for more than four decades. Here is the mechanism, the data, and where it fits.
Melanotan 2 Research Overview
Melanotan 2 is a melanocortin agonist originally developed in academic skin-cancer research. Here is the mechanism and what the literature shows.
Stack Design Principles: How Research Peptide Stacks Are Built
Stacks are not just a marketing concept. Here is how researchers think about combining peptides without doubling up on the same mechanism.
BPC-157 vs TB-500: Two Recovery Peptides, Two Mechanisms
BPC-157 and TB-500 are the two most-cited recovery peptides in the research literature. They have different mechanisms, which is why they are often studied together rather than against each other.
Sermorelin vs CJC-1295 + Ipamorelin: Two Approaches to the GH Pulse
Sermorelin is one molecule, one receptor. CJC-1295 + ipamorelin is two molecules and two receptors. Here is what that means for the GH pulse they produce.
Single, Dual, and Triple Incretin Agonists: The Generation Comparison
Single, dual, triple. Three generations of incretin agonists, each adding one more receptor. Here is the side-by-side comparison of what each generation actually changes.
Want a stack picked for your goals?
The six-step assessment maps your goals, experience, and contraindications to a curated peptide stack. Free, no signup, two minutes.
Take the Assessment